Bioretec signed an agreement with Tri-State Biologics for sales and distribution of implants and instrument sets to hospitals within Greater New York City, Philadelphia, New Jersey, Connecticut and Massachusetts area covering one of the most populated areas of the United States.
As part of the next phase of the RemeOs Trauma Screw commercialization, Bioretec aims to sign more new local sales and distribution agreements to serve civilian hospitals in the U.S. while Spartan Medical continues to serve the military and veteran hospitals.
“We are happy to announce this sales and distribution agreement with a partner who is innovative in forming medical product distribution streams in the U.S. The initial controlled launch of RemeOs Trauma Screws in the U.S. yielded excellent patient results, with a notable number of surgeries and successful post-healing follow-ups. This success lays the groundwork for entering the second phase of commercialization for RemeOs products in the U.S. and driving demand within the surgeon community,” said Alan Donze, CEO of Bioretec Ltd.
Bioretec signed an agreement with Tri-State Biologics for sales and distribution of implants and instrument sets to hospitals within Greater New York City, Philadelphia, New Jersey, Connecticut and Massachusetts area covering one of the most populated areas of the United States.
As part of the next phase of the RemeOs Trauma Screw...
Bioretec signed an agreement with Tri-State Biologics for sales and distribution of implants and instrument sets to hospitals within Greater New York City, Philadelphia, New Jersey, Connecticut and Massachusetts area covering one of the most populated areas of the United States.
As part of the next phase of the RemeOs Trauma Screw commercialization, Bioretec aims to sign more new local sales and distribution agreements to serve civilian hospitals in the U.S. while Spartan Medical continues to serve the military and veteran hospitals.
“We are happy to announce this sales and distribution agreement with a partner who is innovative in forming medical product distribution streams in the U.S. The initial controlled launch of RemeOs Trauma Screws in the U.S. yielded excellent patient results, with a notable number of surgeries and successful post-healing follow-ups. This success lays the groundwork for entering the second phase of commercialization for RemeOs products in the U.S. and driving demand within the surgeon community,” said Alan Donze, CEO of Bioretec Ltd.
Copy to clipboard 
